{smcl}
{com}{sf}{ul off}{txt}{.-}
      name:  {res}<unnamed>
       {txt}log:  {res}C:\Users\k1754142\OneDrive\PhD Project\OpenSAFELY\Github Practice/logs/descriptive_tables.smcl
  {txt}log type:  {res}smcl
 {txt}opened on:  {res} 5 Apr 2022, 19:52:17
{txt}
{com}. 
. **Set Ado file path
. adopath + "$projectdir/analysis/extra_ados"
{txt}  [1]  (BASE)      "{res}C:\Program Files\Stata17\ado\base/{txt}"
  [2]  (SITE)      "{res}C:\Program Files\Stata17\ado\site/{txt}"
  [3]              "{res}.{txt}"
  [4]  (PERSONAL)  "{res}C:\Users\k1754142\ado\personal/{txt}"
  [5]  (PLUS)      "{res}C:\Users\k1754142\ado\plus/{txt}"
  [6]  (OLDPLACE)  "{res}c:\ado/{txt}"
  [7]              "{res}C:\Users\k1754142\OneDrive\PhD Project\OpenSAFELY\Github Practice/analysis/extra_ados{txt}"

{com}. 
. **Use cleaned data from previous step
. use "$projectdir/output/data/file_eia_all.dta", clear
{txt}
{com}. 
. /*Tables=====================================================================================*/
. *Baseline table by eia diagnosis
. preserve
{txt}
{com}. table1_mc, by(eia_diagnosis) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(age contn %3.0f \ ///
>                  agegroup cat %5.1f \ ///
>                  male bin %5.1f \ ///
>                  ethnicity cat %5.1f \ ///
>                  imd cat %5.1f \ ///
>                  bmicat cat %5.1f \ ///
>                  smoke cat %5.1f \ ///
>                  hypertension bin %5.1f \ ///
>                  diabetes bin %5.1f \ ///
>                  hba1ccatmm cat %5.1f \ ///
>                  chronic_cardiac_disease bin %5.1f \ /// 
>                  stroke bin %5.1f \ ///
>                  cancer bin %5.1f \ ///
>                  chronic_resp_disease bin  %5.1f \ ///
>                  chronic_liver_disease bin %5.1f \ ///
>                  ckd cat %5.1f \ ///
>                  egfr_cat_nomiss cat %5.1f \ ///
>                  esrf bin %5.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                             N_T      N_1      N_2      N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Age                             34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Age group                       34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Male                            34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Ethnicity                       34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Index of multiple deprivation   34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}BMI                             34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Smoking status                  34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hypertension                    34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Diabetes                        34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}HbA1c                           34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Chronic cardiac disease         34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Stroke                          34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Cancer                          34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Chronic respiratory disease     34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Chronic liver disease           34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Chronic kidney disease          34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}eGFR                            34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}End-stage renal failure         34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c BLC}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c TRC}
  {c |} {res}                                Total            RA               PsA              AxSpA            p-value {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}                                N=34,096         N=11,315         N=11,288         N=11,493                 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Age                             49 (19)          49 (19)          49 (19)          49 (19)           0.48   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Age group                                                                                            0.99   {txt}{c |}
  {c |} {res}   18-39                        12,471 (36.6%)   4,165 (36.8%)    4,096 (36.3%)    4,210 (36.6%)            {txt}{c |}
  {c |} {res}   40-49                        5,579 (16.4%)    1,845 (16.3%)    1,865 (16.5%)    1,869 (16.3%)            {txt}{c |}
  {c |} {res}   50-59                        5,811 (17.0%)    1,923 (17.0%)    1,918 (17.0%)    1,970 (17.1%)            {txt}{c |}
  {c |} {res}   60-69                        4,614 (13.5%)    1,545 (13.7%)    1,520 (13.5%)    1,549 (13.5%)            {txt}{c |}
  {c |} {res}   70-79                        3,573 (10.5%)    1,179 (10.4%)    1,189 (10.5%)    1,205 (10.5%)            {txt}{c |}
  {c |} {res}   80+                          2,048 (6.0%)     658 (5.8%)       700 (6.2%)       690 (6.0%)               {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Male                            16,671 (48.9%)   5,572 (49.2%)    5,490 (48.6%)    5,609 (48.8%)     0.64   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Ethnicity                                                                                            0.089  {txt}{c |}
  {c |} {res}   White                        12,755 (37.4%)   4,261 (37.7%)    4,254 (37.7%)    4,240 (36.9%)            {txt}{c |}
  {c |} {res}   Asian/Asian British          2,622 (7.7%)     842 (7.4%)       889 (7.9%)       891 (7.8%)               {txt}{c |}
  {c |} {res}   Black                        2,509 (7.4%)     841 (7.4%)       778 (6.9%)       890 (7.7%)               {txt}{c |}
  {c |} {res}   Mixed/Other                  7,593 (22.3%)    2,451 (21.7%)    2,523 (22.4%)    2,619 (22.8%)            {txt}{c |}
  {c |} {res}                                8,617 (25.3%)    2,920 (25.8%)    2,844 (25.2%)    2,853 (24.8%)            {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Index of multiple deprivation                                                                        0.31   {txt}{c |}
  {c |} {res}   1 least deprived             23,868 (70.0%)   7,948 (70.2%)    7,819 (69.3%)    8,101 (70.5%)            {txt}{c |}
  {c |} {res}   4                            6,793 (19.9%)    2,244 (19.8%)    2,293 (20.3%)    2,256 (19.6%)            {txt}{c |}
  {c |} {res}   5 most deprived              3,435 (10.1%)    1,123 (9.9%)     1,176 (10.4%)    1,136 (9.9%)             {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}BMI                                                                                                  0.27   {txt}{c |}
  {c |} {res}   Underweight (<18.5)          68 (0.2%)        21 (0.2%)        18 (0.2%)        29 (0.3%)                {txt}{c |}
  {c |} {res}   Normal (18.5-24.9)           200 (0.6%)       64 (0.6%)        70 (0.6%)        66 (0.6%)                {txt}{c |}
  {c |} {res}   Overweight (25-29.9)         292 (0.9%)       117 (1.0%)       81 (0.7%)        94 (0.8%)                {txt}{c |}
  {c |} {res}   Obese I (30-34.9)            338 (1.0%)       110 (1.0%)       118 (1.0%)       110 (1.0%)               {txt}{c |}
  {c |} {res}   Obese II (35-39.9)           347 (1.0%)       121 (1.1%)       124 (1.1%)       102 (0.9%)               {txt}{c |}
  {c |} {res}   Obese III (40+)              629 (1.8%)       209 (1.8%)       220 (1.9%)       200 (1.7%)               {txt}{c |}
  {c |} {res}                                32,222 (94.5%)   10,673 (94.3%)   10,657 (94.4%)   10,892 (94.8%)           {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Smoking status                                                                                       0.28   {txt}{c |}
  {c |} {res}   Never                        3,403 (10.0%)    1,138 (10.1%)    1,079 (9.6%)     1,186 (10.3%)            {txt}{c |}
  {c |} {res}   Former                       1,663 (4.9%)     542 (4.8%)       574 (5.1%)       547 (4.8%)               {txt}{c |}
  {c |} {res}   Current                      10,298 (30.2%)   3,440 (30.4%)    3,414 (30.2%)    3,444 (30.0%)            {txt}{c |}
  {c |} {res}                                18,732 (54.9%)   6,195 (54.8%)    6,221 (55.1%)    6,316 (55.0%)            {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Hypertension                    6,695 (19.6%)    2,152 (19.0%)    2,250 (19.9%)    2,293 (20.0%)     0.13   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Diabetes                        6,777 (19.9%)    2,236 (19.8%)    2,267 (20.1%)    2,274 (19.8%)     0.80   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}HbA1c                                                                                                0.57   {txt}{c |}
  {c |} {res}   HbA1c <58mmol/mol            1,516 (4.4%)     515 (4.6%)       503 (4.5%)       498 (4.3%)               {txt}{c |}
  {c |} {res}   HbA1c >=58mmol/mol           272 (0.8%)       90 (0.8%)        84 (0.7%)        98 (0.9%)                {txt}{c |}
  {c |} {res}                                32,308 (94.8%)   10,710 (94.7%)   10,701 (94.8%)   10,897 (94.8%)           {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Chronic cardiac disease         6,802 (19.9%)    2,269 (20.1%)    2,211 (19.6%)    2,322 (20.2%)     0.48   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Stroke                          6,870 (20.1%)    2,263 (20.0%)    2,287 (20.3%)    2,320 (20.2%)     0.88   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Cancer                          16,409 (48.1%)   5,450 (48.2%)    5,407 (47.9%)    5,552 (48.3%)     0.82   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Chronic respiratory disease     6,800 (19.9%)    2,296 (20.3%)    2,218 (19.6%)    2,286 (19.9%)     0.47   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Chronic liver disease           6,825 (20.0%)    2,248 (19.9%)    2,251 (19.9%)    2,326 (20.2%)     0.76   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Chronic kidney disease                                                                               0.70   {txt}{c |}
  {c |} {res}   No CKD                       15,162 (44.5%)   5,056 (44.7%)    4,984 (44.2%)    5,122 (44.6%)            {txt}{c |}
  {c |} {res}   CKD                          18,934 (55.5%)   6,259 (55.3%)    6,304 (55.8%)    6,371 (55.4%)            {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}eGFR                                                                                                 0.95   {txt}{c |}
  {c |} {res}   >=60/missing                 19,038 (55.8%)   6,326 (55.9%)    6,275 (55.6%)    6,437 (56.0%)            {txt}{c |}
  {c |} {res}   30-59                        9,058 (26.6%)    3,016 (26.7%)    3,011 (26.7%)    3,031 (26.4%)            {txt}{c |}
  {c |} {res}   <30                          6,000 (17.6%)    1,973 (17.4%)    2,002 (17.7%)    2,025 (17.6%)            {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}End-stage renal failure         6,940 (20.4%)    2,291 (20.2%)    2,357 (20.9%)    2,292 (19.9%)     0.20   {txt}{c |}
  {c BLC}{hline 31}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c BRC}
Data are presented as mean (SD) for continuous measures, and n (%) for categorical measures.
 

{com}. restore
{txt}
{com}. 
. *Baseline table by year of diagnosis
. preserve
{txt}
{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(age contn %3.0f \ ///
>                  agegroup cat %5.1f \ ///
>                  male bin %5.1f \ ///
>                  ethnicity cat %5.1f \ ///
>                  imd cat %5.1f \ ///
>                  bmicat cat %5.1f \ ///
>                  smoke cat %5.1f \ ///
>                  hypertension bin %5.1f \ ///
>                  diabetes bin %5.1f \ ///
>                  hba1ccatmm cat %5.1f \ ///
>                  chronic_cardiac_disease bin %5.1f \ /// 
>                  stroke bin %5.1f \ ///
>                  cancer bin %5.1f \ ///
>                  chronic_resp_disease bin  %5.1f \ ///
>                  chronic_liver_disease bin %5.1f \ ///
>                  ckd cat %5.1f \ ///
>                  egfr_cat_nomiss cat %5.1f \ ///
>                  esrf bin %5.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                             N_T      N_1      N_2      N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Age                             32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Age group                       32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Male                            32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Ethnicity                       32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Index of multiple deprivation   32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}BMI                             32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Smoking status                  32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hypertension                    32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Diabetes                        32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}HbA1c                           32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Chronic cardiac disease         32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Stroke                          32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Cancer                          32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Chronic respiratory disease     32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Chronic liver disease           32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Chronic kidney disease          32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}eGFR                            32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}End-stage renal failure         32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c BLC}{hline 31}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                Total            March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                N=32,644         N=10,917                N=10,897                N=10,830                        {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Age                             49 (19)          48 (19)                 49 (19)                 49 (19)                  0.20   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Age group                                                                                                                 0.31   {txt}{c |}
  {c |} {res}   18-39                        11,934 (36.6%)   4,002 (36.7%)           4,042 (37.1%)           3,890 (35.9%)                   {txt}{c |}
  {c |} {res}   40-49                        5,340 (16.4%)    1,801 (16.5%)           1,734 (15.9%)           1,805 (16.7%)                   {txt}{c |}
  {c |} {res}   50-59                        5,537 (17.0%)    1,887 (17.3%)           1,810 (16.6%)           1,840 (17.0%)                   {txt}{c |}
  {c |} {res}   60-69                        4,434 (13.6%)    1,493 (13.7%)           1,483 (13.6%)           1,458 (13.5%)                   {txt}{c |}
  {c |} {res}   70-79                        3,444 (10.6%)    1,104 (10.1%)           1,184 (10.9%)           1,156 (10.7%)                   {txt}{c |}
  {c |} {res}   80+                          1,955 (6.0%)     630 (5.8%)              644 (5.9%)              681 (6.3%)                      {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Male                            16,005 (49.0%)   5,329 (48.8%)           5,391 (49.5%)           5,285 (48.8%)            0.53   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Ethnicity                                                                                                                 0.89   {txt}{c |}
  {c |} {res}   White                        12,215 (37.4%)   4,141 (37.9%)           4,053 (37.2%)           4,021 (37.1%)                   {txt}{c |}
  {c |} {res}   Asian/Asian British          2,510 (7.7%)     845 (7.7%)              824 (7.6%)              841 (7.8%)                      {txt}{c |}
  {c |} {res}   Black                        2,411 (7.4%)     797 (7.3%)              832 (7.6%)              782 (7.2%)                      {txt}{c |}
  {c |} {res}   Mixed/Other                  7,272 (22.3%)    2,441 (22.4%)           2,415 (22.2%)           2,416 (22.3%)                   {txt}{c |}
  {c |} {res}                                8,236 (25.2%)    2,693 (24.7%)           2,773 (25.4%)           2,770 (25.6%)                   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Index of multiple deprivation                                                                                             0.69   {txt}{c |}
  {c |} {res}   1 least deprived             22,880 (70.1%)   7,596 (69.6%)           7,676 (70.4%)           7,608 (70.2%)                   {txt}{c |}
  {c |} {res}   4                            6,481 (19.9%)    2,200 (20.2%)           2,135 (19.6%)           2,146 (19.8%)                   {txt}{c |}
  {c |} {res}   5 most deprived              3,283 (10.1%)    1,121 (10.3%)           1,086 (10.0%)           1,076 (9.9%)                    {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}BMI                                                                                                                       0.33   {txt}{c |}
  {c |} {res}   Underweight (<18.5)          64 (0.2%)        26 (0.2%)               23 (0.2%)               15 (0.1%)                       {txt}{c |}
  {c |} {res}   Normal (18.5-24.9)           193 (0.6%)       63 (0.6%)               76 (0.7%)               54 (0.5%)                       {txt}{c |}
  {c |} {res}   Overweight (25-29.9)         281 (0.9%)       112 (1.0%)              88 (0.8%)               81 (0.7%)                       {txt}{c |}
  {c |} {res}   Obese I (30-34.9)            326 (1.0%)       125 (1.1%)              98 (0.9%)               103 (1.0%)                      {txt}{c |}
  {c |} {res}   Obese II (35-39.9)           337 (1.0%)       115 (1.1%)              109 (1.0%)              113 (1.0%)                      {txt}{c |}
  {c |} {res}   Obese III (40+)              606 (1.9%)       243 (2.2%)              186 (1.7%)              177 (1.6%)                      {txt}{c |}
  {c |} {res}                                30,837 (94.5%)   10,233 (93.7%)          10,317 (94.7%)          10,287 (95.0%)                  {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Smoking status                                                                                                            0.87   {txt}{c |}
  {c |} {res}   Never                        3,249 (10.0%)    1,119 (10.3%)           1,062 (9.7%)            1,068 (9.9%)                    {txt}{c |}
  {c |} {res}   Former                       1,590 (4.9%)     534 (4.9%)              534 (4.9%)              522 (4.8%)                      {txt}{c |}
  {c |} {res}   Current                      9,841 (30.1%)    3,296 (30.2%)           3,305 (30.3%)           3,240 (29.9%)                   {txt}{c |}
  {c |} {res}                                17,964 (55.0%)   5,968 (54.7%)           5,996 (55.0%)           6,000 (55.4%)                   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hypertension                    6,401 (19.6%)    2,153 (19.7%)           2,155 (19.8%)           2,093 (19.3%)            0.66   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Diabetes                        6,514 (20.0%)    2,203 (20.2%)           2,162 (19.8%)           2,149 (19.8%)            0.77   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}HbA1c                                                                                                                     0.96   {txt}{c |}
  {c |} {res}   HbA1c <58mmol/mol            1,485 (4.5%)     634 (5.8%)              495 (4.5%)              356 (3.3%)                      {txt}{c |}
  {c |} {res}   HbA1c >=58mmol/mol           266 (0.8%)       116 (1.1%)              88 (0.8%)               62 (0.6%)                       {txt}{c |}
  {c |} {res}                                30,893 (94.6%)   10,167 (93.1%)          10,314 (94.6%)          10,412 (96.1%)                  {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Chronic cardiac disease         6,510 (19.9%)    2,201 (20.2%)           2,202 (20.2%)           2,107 (19.5%)            0.30   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Stroke                          6,582 (20.2%)    2,121 (19.4%)           2,226 (20.4%)           2,235 (20.6%)            0.059  {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Cancer                          15,704 (48.1%)   5,135 (47.0%)           5,253 (48.2%)           5,316 (49.1%)            0.010  {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Chronic respiratory disease     6,522 (20.0%)    2,169 (19.9%)           2,158 (19.8%)           2,195 (20.3%)            0.65   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Chronic liver disease           6,530 (20.0%)    2,178 (20.0%)           2,143 (19.7%)           2,209 (20.4%)            0.40   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Chronic kidney disease                                                                                                    0.33   {txt}{c |}
  {c |} {res}   No CKD                       14,473 (44.3%)   4,853 (44.5%)           4,878 (44.8%)           4,742 (43.8%)                   {txt}{c |}
  {c |} {res}   CKD                          18,171 (55.7%)   6,064 (55.5%)           6,019 (55.2%)           6,088 (56.2%)                   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}eGFR                                                                                                                      0.13   {txt}{c |}
  {c |} {res}   >=60/missing                 18,191 (55.7%)   6,114 (56.0%)           6,149 (56.4%)           5,928 (54.7%)                   {txt}{c |}
  {c |} {res}   30-59                        8,703 (26.7%)    2,875 (26.3%)           2,868 (26.3%)           2,960 (27.3%)                   {txt}{c |}
  {c |} {res}   <30                          5,750 (17.6%)    1,928 (17.7%)           1,880 (17.3%)           1,942 (17.9%)                   {txt}{c |}
  {c LT}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}End-stage renal failure         6,674 (20.4%)    2,280 (20.9%)           2,186 (20.1%)           2,208 (20.4%)            0.31   {txt}{c |}
  {c BLC}{hline 31}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as mean (SD) for continuous measures, and n (%) for categorical measures.
 

{com}. restore
{txt}
{com}. 
. *Referral standards, by eia diagnosis
. preserve
{txt}
{com}. table1_mc, by(eia_diagnosis) total(before) onecol nospacelowpercent iqrmiddle(",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 33}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c TRC}
  {c |} {res}factor                              N_T     N_1     N_2     N_3      m_T      m_1      m_2      m_3 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c RT}
  {c |} {res}Time to GP referral                 914     326     303     285   33,182   10,989   10,985   11,208 {txt}{c |}
  {c |} {res}Time to GP referral                 914     326     303     285   33,182   10,989   10,985   11,208 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c RT}
  {c |} {res}Time to rheumatology assessment   5,184   1,735   1,705   1,744   28,912    9,580    9,583    9,749 {txt}{c |}
  {c |} {res}Time to rheumatology assessment   5,184   1,735   1,705   1,744   28,912    9,580    9,583    9,749 {txt}{c |}
  {c BLC}{hline 33}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 33}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c TRC}
  {c |} {res}                                  Total           RA              PsA             AxSpA           p-value {txt}{c |}
  {c LT}{hline 33}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}                                  N=34,096        N=11,315        N=11,288        N=11,493                {txt}{c |}
  {c LT}{hline 33}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Time to GP referral                                                                                0.84   {txt}{c |}
  {c |} {res}   Referred within 3 days         11 (1.2%)       3 (0.9%)        3 (1.0%)        5 (1.8%)                {txt}{c |}
  {c |} {res}   Referred within 7 days         12 (1.3%)       5 (1.5%)        3 (1.0%)        4 (1.4%)                {txt}{c |}
  {c |} {res}   Referral delay >7 days         891 (97.5%)     318 (97.5%)     297 (98.0%)     276 (96.8%)             {txt}{c |}
  {c |} {res}Time to GP referral                                                                                0.59   {txt}{c |}
  {c |} {res}   Referred within 3 days         11 (1.2%)       3 (0.9%)        3 (1.0%)        5 (1.8%)                {txt}{c |}
  {c |} {res}   Referral delay >3 days         903 (98.8%)     323 (99.1%)     300 (99.0%)     280 (98.2%)             {txt}{c |}
  {c LT}{hline 33}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Time to rheumatology assessment                                                                    0.83   {txt}{c |}
  {c |} {res}   Seen within 3 weeks            298 (5.7%)      93 (5.4%)       97 (5.7%)       108 (6.2%)              {txt}{c |}
  {c |} {res}   Seen within 6 weeks            242 (4.7%)      82 (4.7%)       83 (4.9%)       77 (4.4%)               {txt}{c |}
  {c |} {res}   Assessment delay >6 weeks      4,644 (89.6%)   1,560 (89.9%)   1,525 (89.4%)   1,559 (89.4%)           {txt}{c |}
  {c |} {res}Time to rheumatology assessment                                                                    0.57   {txt}{c |}
  {c |} {res}   Seen within 3 weeks            298 (5.7%)      93 (5.4%)       97 (5.7%)       108 (6.2%)              {txt}{c |}
  {c |} {res}   Assessment delay >3 weeks      4,886 (94.3%)   1,642 (94.6%)   1,608 (94.3%)   1,636 (93.8%)           {txt}{c |}
  {c BLC}{hline 33}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. **With missing data
. preserve
{txt}
{com}. table1_mc, by(eia_diagnosis) total(before) missing onecol nospacelowpercent iqrmiddle(",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 33}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                               N_T      N_1      N_2      N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Time to GP referral               34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c |} {res}Time to GP referral               34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Time to rheumatology assessment   34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c |} {res}Time to rheumatology assessment   34,096   11,315   11,288   11,493     0     0     0     0 {txt}{c |}
  {c BLC}{hline 33}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 33}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c TRC}
  {c |} {res}                                  Total            RA               PsA              AxSpA            p-value {txt}{c |}
  {c LT}{hline 33}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}                                  N=34,096         N=11,315         N=11,288         N=11,493                 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Time to GP referral                                                                                    0.84   {txt}{c |}
  {c |} {res}   Referred within 3 days         11 (0.0%)        3 (0.0%)         3 (0.0%)         5 (0.0%)                 {txt}{c |}
  {c |} {res}   Referred within 7 days         12 (0.0%)        5 (0.0%)         3 (0.0%)         4 (0.0%)                 {txt}{c |}
  {c |} {res}   Referral delay >7 days         891 (2.6%)       318 (2.8%)       297 (2.6%)       276 (2.4%)               {txt}{c |}
  {c |} {res}   Missing                        33,182 (97.3%)   10,989 (97.1%)   10,985 (97.3%)   11,208 (97.5%)           {txt}{c |}
  {c |} {res}Time to GP referral                                                                                    0.59   {txt}{c |}
  {c |} {res}   Referred within 3 days         11 (0.0%)        3 (0.0%)         3 (0.0%)         5 (0.0%)                 {txt}{c |}
  {c |} {res}   Referral delay >3 days         903 (2.6%)       323 (2.9%)       300 (2.7%)       280 (2.4%)               {txt}{c |}
  {c |} {res}   Missing                        33,182 (97.3%)   10,989 (97.1%)   10,985 (97.3%)   11,208 (97.5%)           {txt}{c |}
  {c LT}{hline 33}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Time to rheumatology assessment                                                                        0.83   {txt}{c |}
  {c |} {res}   Seen within 3 weeks            298 (0.9%)       93 (0.8%)        97 (0.9%)        108 (0.9%)               {txt}{c |}
  {c |} {res}   Seen within 6 weeks            242 (0.7%)       82 (0.7%)        83 (0.7%)        77 (0.7%)                {txt}{c |}
  {c |} {res}   Assessment delay >6 weeks      4,644 (13.6%)    1,560 (13.8%)    1,525 (13.5%)    1,559 (13.6%)            {txt}{c |}
  {c |} {res}   Missing                        28,912 (84.8%)   9,580 (84.7%)    9,583 (84.9%)    9,749 (84.8%)            {txt}{c |}
  {c |} {res}Time to rheumatology assessment                                                                        0.57   {txt}{c |}
  {c |} {res}   Seen within 3 weeks            298 (0.9%)       93 (0.8%)        97 (0.9%)        108 (0.9%)               {txt}{c |}
  {c |} {res}   Assessment delay >3 weeks      4,886 (14.3%)    1,642 (14.5%)    1,608 (14.2%)    1,636 (14.2%)            {txt}{c |}
  {c |} {res}   Missing                        28,912 (84.8%)   9,580 (84.7%)    9,583 (84.9%)    9,749 (84.8%)            {txt}{c |}
  {c BLC}{hline 33}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Referral standards, by year of diagnosis
. preserve
{txt}
{com}. table1_mc, by(diagnosis_year) total(before) onecol nospacelowpercent iqrmiddle(",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 33}{c -}{hline 7}{c -}{hline 5}{c -}{hline 7}{c -}{hline 7}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c TRC}
  {c |} {res}factor                              N_T   N_1     N_2     N_3      m_T      m_1      m_2      m_3 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 7}{c -}{hline 5}{c -}{hline 7}{c -}{hline 7}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c RT}
  {c |} {res}Time to GP referral                 826    92     252     482   31,818   10,825   10,645   10,348 {txt}{c |}
  {c |} {res}Time to GP referral                 826    92     252     482   31,818   10,825   10,645   10,348 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 7}{c -}{hline 5}{c -}{hline 7}{c -}{hline 7}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c RT}
  {c |} {res}Time to rheumatology assessment   4,830   865   1,660   2,305   27,814   10,052    9,237    8,525 {txt}{c |}
  {c |} {res}Time to rheumatology assessment   4,830   865   1,660   2,305   27,814   10,052    9,237    8,525 {txt}{c |}
  {c BLC}{hline 33}{c -}{hline 7}{c -}{hline 5}{c -}{hline 7}{c -}{hline 7}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 33}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                  Total           March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 33}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                  N=32,644        N=10,917                N=10,897                N=10,830                        {txt}{c |}
  {c LT}{hline 33}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Time to GP referral                                                                                                        0.31   {txt}{c |}
  {c |} {res}   Referred within 3 days         11 (1.3%)       3 (3.3%)                4 (1.6%)                4 (0.8%)                        {txt}{c |}
  {c |} {res}   Referred within 7 days         11 (1.3%)       2 (2.2%)                2 (0.8%)                7 (1.5%)                        {txt}{c |}
  {c |} {res}   Referral delay >7 days         804 (97.3%)     87 (94.6%)              246 (97.6%)             471 (97.7%)                     {txt}{c |}
  {c |} {res}Time to GP referral                                                                                                        0.16   {txt}{c |}
  {c |} {res}   Referred within 3 days         11 (1.3%)       3 (3.3%)                4 (1.6%)                4 (0.8%)                        {txt}{c |}
  {c |} {res}   Referral delay >3 days         815 (98.7%)     89 (96.7%)              248 (98.4%)             478 (99.2%)                     {txt}{c |}
  {c LT}{hline 33}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Time to rheumatology assessment                                                                                           <0.001  {txt}{c |}
  {c |} {res}   Seen within 3 weeks            286 (5.9%)      69 (8.0%)               91 (5.5%)               126 (5.5%)                      {txt}{c |}
  {c |} {res}   Seen within 6 weeks            229 (4.7%)      59 (6.8%)               79 (4.8%)               91 (3.9%)                       {txt}{c |}
  {c |} {res}   Assessment delay >6 weeks      4,315 (89.3%)   737 (85.2%)             1,490 (89.8%)           2,088 (90.6%)                   {txt}{c |}
  {c |} {res}Time to rheumatology assessment                                                                                            0.018  {txt}{c |}
  {c |} {res}   Seen within 3 weeks            286 (5.9%)      69 (8.0%)               91 (5.5%)               126 (5.5%)                      {txt}{c |}
  {c |} {res}   Assessment delay >3 weeks      4,544 (94.1%)   796 (92.0%)             1,569 (94.5%)           2,179 (94.5%)                   {txt}{c |}
  {c BLC}{hline 33}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
. **With missing data
. preserve
{txt}
{com}. table1_mc, by(diagnosis_year) total(before) missing onecol nospacelowpercent iqrmiddle(",")  ///
>         vars(gp_ref_cat cat %3.1f \ ///
>                  gp_ref_3d cat %3.1f \ ///
>                  ref_appt_cat cat %3.1f \ ///
>                  ref_appt_3w cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 33}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                               N_T      N_1      N_2      N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Time to GP referral               32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c |} {res}Time to GP referral               32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c LT}{hline 33}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Time to rheumatology assessment   32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c |} {res}Time to rheumatology assessment   32,644   10,917   10,897   10,830     0     0     0     0 {txt}{c |}
  {c BLC}{hline 33}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 33}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                  Total            March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 33}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                  N=32,644         N=10,917                N=10,897                N=10,830                        {txt}{c |}
  {c LT}{hline 33}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Time to GP referral                                                                                                         0.31   {txt}{c |}
  {c |} {res}   Referred within 3 days         11 (0.0%)        3 (0.0%)                4 (0.0%)                4 (0.0%)                        {txt}{c |}
  {c |} {res}   Referred within 7 days         11 (0.0%)        2 (0.0%)                2 (0.0%)                7 (0.1%)                        {txt}{c |}
  {c |} {res}   Referral delay >7 days         804 (2.5%)       87 (0.8%)               246 (2.3%)              471 (4.3%)                      {txt}{c |}
  {c |} {res}   Missing                        31,818 (97.5%)   10,825 (99.2%)          10,645 (97.7%)          10,348 (95.5%)                  {txt}{c |}
  {c |} {res}Time to GP referral                                                                                                         0.16   {txt}{c |}
  {c |} {res}   Referred within 3 days         11 (0.0%)        3 (0.0%)                4 (0.0%)                4 (0.0%)                        {txt}{c |}
  {c |} {res}   Referral delay >3 days         815 (2.5%)       89 (0.8%)               248 (2.3%)              478 (4.4%)                      {txt}{c |}
  {c |} {res}   Missing                        31,818 (97.5%)   10,825 (99.2%)          10,645 (97.7%)          10,348 (95.5%)                  {txt}{c |}
  {c LT}{hline 33}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Time to rheumatology assessment                                                                                            <0.001  {txt}{c |}
  {c |} {res}   Seen within 3 weeks            286 (0.9%)       69 (0.6%)               91 (0.8%)               126 (1.2%)                      {txt}{c |}
  {c |} {res}   Seen within 6 weeks            229 (0.7%)       59 (0.5%)               79 (0.7%)               91 (0.8%)                       {txt}{c |}
  {c |} {res}   Assessment delay >6 weeks      4,315 (13.2%)    737 (6.8%)              1,490 (13.7%)           2,088 (19.3%)                   {txt}{c |}
  {c |} {res}   Missing                        27,814 (85.2%)   10,052 (92.1%)          9,237 (84.8%)           8,525 (78.7%)                   {txt}{c |}
  {c |} {res}Time to rheumatology assessment                                                                                             0.018  {txt}{c |}
  {c |} {res}   Seen within 3 weeks            286 (0.9%)       69 (0.6%)               91 (0.8%)               126 (1.2%)                      {txt}{c |}
  {c |} {res}   Assessment delay >3 weeks      4,544 (13.9%)    796 (7.3%)              1,569 (14.4%)           2,179 (20.1%)                   {txt}{c |}
  {c |} {res}   Missing                        27,814 (85.2%)   10,052 (92.1%)          9,237 (84.8%)           8,525 (78.7%)                   {txt}{c |}
  {c BLC}{hline 33}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Drug prescription table at 6 months, for those with at least 6m registration
. preserve
{txt}
{com}. keep if has_6m_follow_up==1
{txt}(1,731 observations deleted)

{com}. table1_mc, by(eia_diagnosis) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                  N_T      N_1      N_2      N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 6 months              32,365   10,704   10,742   10,919     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 6 months         32,365   10,704   10,742   10,919     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 6 months        32,365   10,704   10,742   10,919     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months   32,365   10,704   10,742   10,919     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 6 months          32,365   10,704   10,742   10,919     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months       32,365   10,704   10,742   10,919     0     0     0     0 {txt}{c |}
  {c BLC}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c TRC}
  {c |} {res}                                     Total            RA              PsA              AxSpA            p-value {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}                                     N=32,365         N=10,704        N=10,742         N=10,919                 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 6 months                                                                                  0.68   {txt}{c |}
  {c |} {res}   Yes                               1,393 (4.3%)     469 (4.4%)      445 (4.1%)       479 (4.4%)               {txt}{c |}
  {c |} {res}   No                                7,978 (24.7%)    2,659 (24.8%)   2,642 (24.6%)    2,677 (24.5%)            {txt}{c |}
  {c |} {res}   Missing                           22,994 (71.0%)   7,576 (70.8%)   7,655 (71.3%)    7,763 (71.1%)            {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 6 months                                                                             0.37   {txt}{c |}
  {c |} {res}   Yes                               582 (1.8%)       194 (1.8%)      179 (1.7%)       209 (1.9%)               {txt}{c |}
  {c |} {res}   No                                3,652 (11.3%)    1,244 (11.6%)   1,201 (11.2%)    1,207 (11.1%)            {txt}{c |}
  {c |} {res}   Missing                           28,131 (86.9%)   9,266 (86.6%)   9,362 (87.2%)    9,503 (87.0%)            {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 6 months                                                                            0.80   {txt}{c |}
  {c |} {res}   Yes                               280 (0.9%)       90 (0.8%)       94 (0.9%)        96 (0.9%)                {txt}{c |}
  {c |} {res}   No                                1,974 (6.1%)     661 (6.2%)      675 (6.3%)       638 (5.8%)               {txt}{c |}
  {c |} {res}   Missing                           30,111 (93.0%)   9,953 (93.0%)   9,973 (92.8%)    10,185 (93.3%)           {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months                                                                       0.32   {txt}{c |}
  {c |} {res}   Yes                               308 (1.0%)       110 (1.0%)      104 (1.0%)       94 (0.9%)                {txt}{c |}
  {c |} {res}   No                                1,967 (6.1%)     653 (6.1%)      627 (5.8%)       687 (6.3%)               {txt}{c |}
  {c |} {res}   Missing                           30,090 (93.0%)   9,941 (92.9%)   10,011 (93.2%)   10,138 (92.8%)           {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 6 months                                                                              0.96   {txt}{c |}
  {c |} {res}   Yes                               266 (0.8%)       88 (0.8%)       84 (0.8%)        94 (0.9%)                {txt}{c |}
  {c |} {res}   No                                1,956 (6.0%)     653 (6.1%)      628 (5.8%)       675 (6.2%)               {txt}{c |}
  {c |} {res}   Missing                           30,143 (93.1%)   9,963 (93.1%)   10,030 (93.4%)   10,150 (93.0%)           {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months                                                                           0.44   {txt}{c |}
  {c |} {res}   Yes                               4,184 (12.9%)    1,360 (12.7%)   1,375 (12.8%)    1,449 (13.3%)            {txt}{c |}
  {c |} {res}   No                                15,180 (46.9%)   5,020 (46.9%)   5,063 (47.1%)    5,097 (46.7%)            {txt}{c |}
  {c |} {res}   Missing                           13,001 (40.2%)   4,324 (40.4%)   4,304 (40.1%)    4,373 (40.0%)            {txt}{c |}
  {c BLC}{hline 36}{c -}{hline 16}{c -}{hline 15}{c -}{hline 16}{c -}{hline 16}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Drug prescription table at 12 months, for those with at least 12m registration
. preserve
{txt}
{com}. keep if has_12m_follow_up==1
{txt}(3,405 observations deleted)

{com}. table1_mc, by(eia_diagnosis) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_12m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                   N_T      N_1      N_2      N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 12 months              30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 12 months         30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 12 months        30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months   30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 12 months          30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months       30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c TRC}
  {c |} {res}                                      Total            RA              PsA             AxSpA           p-value {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}                                      N=30,691         N=10,245        N=10,140        N=10,306                {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 12 months                                                                                0.45   {txt}{c |}
  {c |} {res}   Yes                                2,925 (9.5%)     989 (9.7%)      932 (9.2%)      1,004 (9.7%)            {txt}{c |}
  {c |} {res}   No                                 5,960 (19.4%)    2,002 (19.5%)   1,974 (19.5%)   1,984 (19.3%)           {txt}{c |}
  {c |} {res}   Missing                            21,806 (71.1%)   7,254 (70.8%)   7,234 (71.3%)   7,318 (71.0%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 12 months                                                                           0.91   {txt}{c |}
  {c |} {res}   Yes                                1,239 (4.0%)     427 (4.2%)      395 (3.9%)      417 (4.0%)              {txt}{c |}
  {c |} {res}   No                                 2,777 (9.0%)     948 (9.3%)      905 (8.9%)      924 (9.0%)              {txt}{c |}
  {c |} {res}   Missing                            26,675 (86.9%)   8,870 (86.6%)   8,840 (87.2%)   8,965 (87.0%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 12 months                                                                          0.11   {txt}{c |}
  {c |} {res}   Yes                                606 (2.0%)       196 (1.9%)      194 (1.9%)      216 (2.1%)              {txt}{c |}
  {c |} {res}   No                                 1,521 (5.0%)     520 (5.1%)      530 (5.2%)      471 (4.6%)              {txt}{c |}
  {c |} {res}   Missing                            28,564 (93.1%)   9,529 (93.0%)   9,416 (92.9%)   9,619 (93.3%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months                                                                     0.28   {txt}{c |}
  {c |} {res}   Yes                                648 (2.1%)       227 (2.2%)      211 (2.1%)      210 (2.0%)              {txt}{c |}
  {c |} {res}   No                                 1,517 (4.9%)     493 (4.8%)      480 (4.7%)      544 (5.3%)              {txt}{c |}
  {c |} {res}   Missing                            28,526 (92.9%)   9,525 (93.0%)   9,449 (93.2%)   9,552 (92.7%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 12 months                                                                            0.52   {txt}{c |}
  {c |} {res}   Yes                                596 (1.9%)       198 (1.9%)      181 (1.8%)      217 (2.1%)              {txt}{c |}
  {c |} {res}   No                                 1,514 (4.9%)     514 (5.0%)      487 (4.8%)      513 (5.0%)              {txt}{c |}
  {c |} {res}   Missing                            28,581 (93.1%)   9,533 (93.1%)   9,472 (93.4%)   9,576 (92.9%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months                                                                         0.98   {txt}{c |}
  {c |} {res}   Yes                                8,323 (27.1%)    2,767 (27.0%)   2,748 (27.1%)   2,808 (27.2%)           {txt}{c |}
  {c |} {res}   No                                 10,032 (32.7%)   3,341 (32.6%)   3,299 (32.5%)   3,392 (32.9%)           {txt}{c |}
  {c |} {res}   Missing                            12,336 (40.2%)   4,137 (40.4%)   4,093 (40.4%)   4,106 (39.8%)           {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Drug prescription table at 6 and 12 months, for those with at least 12m registration
. preserve
{txt}
{com}. keep if has_12m_follow_up==1
{txt}(3,405 observations deleted)

{com}. table1_mc, by(eia_diagnosis) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  csdmard_12m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                   N_T      N_1      N_2      N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 6 months               30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 12 months              30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 6 months          30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 12 months         30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 6 months         30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 12 months        30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months    30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months   30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 6 months           30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 12 months          30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months        30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months       30,691   10,245   10,140   10,306     0     0     0     0 {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c TRC}
  {c |} {res}                                      Total            RA              PsA             AxSpA           p-value {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}                                      N=30,691         N=10,245        N=10,140        N=10,306                {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 6 months                                                                                 0.59   {txt}{c |}
  {c |} {res}   Yes                                1,315 (4.3%)     445 (4.3%)      415 (4.1%)      455 (4.4%)              {txt}{c |}
  {c |} {res}   No                                 7,570 (24.7%)    2,546 (24.9%)   2,491 (24.6%)   2,533 (24.6%)           {txt}{c |}
  {c |} {res}   Missing                            21,806 (71.1%)   7,254 (70.8%)   7,234 (71.3%)   7,318 (71.0%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 12 months                                                                                0.45   {txt}{c |}
  {c |} {res}   Yes                                2,925 (9.5%)     989 (9.7%)      932 (9.2%)      1,004 (9.7%)            {txt}{c |}
  {c |} {res}   No                                 5,960 (19.4%)    2,002 (19.5%)   1,974 (19.5%)   1,984 (19.3%)           {txt}{c |}
  {c |} {res}   Missing                            21,806 (71.1%)   7,254 (70.8%)   7,234 (71.3%)   7,318 (71.0%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 6 months                                                                            0.51   {txt}{c |}
  {c |} {res}   Yes                                549 (1.8%)       187 (1.8%)      168 (1.7%)      194 (1.9%)              {txt}{c |}
  {c |} {res}   No                                 3,467 (11.3%)    1,188 (11.6%)   1,132 (11.2%)   1,147 (11.1%)           {txt}{c |}
  {c |} {res}   Missing                            26,675 (86.9%)   8,870 (86.6%)   8,840 (87.2%)   8,965 (87.0%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 12 months                                                                           0.91   {txt}{c |}
  {c |} {res}   Yes                                1,239 (4.0%)     427 (4.2%)      395 (3.9%)      417 (4.0%)              {txt}{c |}
  {c |} {res}   No                                 2,777 (9.0%)     948 (9.3%)      905 (8.9%)      924 (9.0%)              {txt}{c |}
  {c |} {res}   Missing                            26,675 (86.9%)   8,870 (86.6%)   8,840 (87.2%)   8,965 (87.0%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 6 months                                                                           0.36   {txt}{c |}
  {c |} {res}   Yes                                256 (0.8%)       77 (0.8%)       88 (0.9%)       91 (0.9%)               {txt}{c |}
  {c |} {res}   No                                 1,871 (6.1%)     639 (6.2%)      636 (6.3%)      596 (5.8%)              {txt}{c |}
  {c |} {res}   Missing                            28,564 (93.1%)   9,529 (93.0%)   9,416 (92.9%)   9,619 (93.3%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 12 months                                                                          0.11   {txt}{c |}
  {c |} {res}   Yes                                606 (2.0%)       196 (1.9%)      194 (1.9%)      216 (2.1%)              {txt}{c |}
  {c |} {res}   No                                 1,521 (5.0%)     520 (5.1%)      530 (5.2%)      471 (4.6%)              {txt}{c |}
  {c |} {res}   Missing                            28,564 (93.1%)   9,529 (93.0%)   9,416 (92.9%)   9,619 (93.3%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months                                                                      0.32   {txt}{c |}
  {c |} {res}   Yes                                294 (1.0%)       104 (1.0%)      99 (1.0%)       91 (0.9%)               {txt}{c |}
  {c |} {res}   No                                 1,871 (6.1%)     616 (6.0%)      592 (5.8%)      663 (6.4%)              {txt}{c |}
  {c |} {res}   Missing                            28,526 (92.9%)   9,525 (93.0%)   9,449 (93.2%)   9,552 (92.7%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months                                                                     0.28   {txt}{c |}
  {c |} {res}   Yes                                648 (2.1%)       227 (2.2%)      211 (2.1%)      210 (2.0%)              {txt}{c |}
  {c |} {res}   No                                 1,517 (4.9%)     493 (4.8%)      480 (4.7%)      544 (5.3%)              {txt}{c |}
  {c |} {res}   Missing                            28,526 (92.9%)   9,525 (93.0%)   9,449 (93.2%)   9,552 (92.7%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 6 months                                                                             0.76   {txt}{c |}
  {c |} {res}   Yes                                256 (0.8%)       88 (0.9%)       76 (0.7%)       92 (0.9%)               {txt}{c |}
  {c |} {res}   No                                 1,854 (6.0%)     624 (6.1%)      592 (5.8%)      638 (6.2%)              {txt}{c |}
  {c |} {res}   Missing                            28,581 (93.1%)   9,533 (93.1%)   9,472 (93.4%)   9,576 (92.9%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 12 months                                                                            0.52   {txt}{c |}
  {c |} {res}   Yes                                596 (1.9%)       198 (1.9%)      181 (1.8%)      217 (2.1%)              {txt}{c |}
  {c |} {res}   No                                 1,514 (4.9%)     514 (5.0%)      487 (4.8%)      513 (5.0%)              {txt}{c |}
  {c |} {res}   Missing                            28,581 (93.1%)   9,533 (93.1%)   9,472 (93.4%)   9,576 (92.9%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months                                                                          0.15   {txt}{c |}
  {c |} {res}   Yes                                3,979 (13.0%)    1,278 (12.5%)   1,315 (13.0%)   1,386 (13.4%)           {txt}{c |}
  {c |} {res}   No                                 14,376 (46.8%)   4,830 (47.1%)   4,732 (46.7%)   4,814 (46.7%)           {txt}{c |}
  {c |} {res}   Missing                            12,336 (40.2%)   4,137 (40.4%)   4,093 (40.4%)   4,106 (39.8%)           {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months                                                                         0.98   {txt}{c |}
  {c |} {res}   Yes                                8,323 (27.1%)    2,767 (27.0%)   2,748 (27.1%)   2,808 (27.2%)           {txt}{c |}
  {c |} {res}   No                                 10,032 (32.7%)   3,341 (32.6%)   3,299 (32.5%)   3,392 (32.9%)           {txt}{c |}
  {c |} {res}   Missing                            12,336 (40.2%)   4,137 (40.4%)   4,093 (40.4%)   4,106 (39.8%)           {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 16}{c -}{hline 15}{c -}{hline 15}{c -}{hline 15}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Drug prescription table at 6 months, for those with at least 6m registration, for all patients by year of diagnosis
. preserve
{txt}
{com}. keep if has_6m_follow_up==1
{txt}(1,731 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                  N_T      N_1      N_2      N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 6 months              30,994   10,359   10,381   10,254     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 6 months         30,994   10,359   10,381   10,254     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 6 months        30,994   10,359   10,381   10,254     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months   30,994   10,359   10,381   10,254     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 6 months          30,994   10,359   10,381   10,254     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months       30,994   10,359   10,381   10,254     0     0     0     0 {txt}{c |}
  {c BLC}{hline 36}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 8}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                     Total            March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                     N=30,994         N=10,359                N=10,381                N=10,254                        {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 6 months                                                                                                        0.81   {txt}{c |}
  {c |} {res}   Yes                               1,335 (4.3%)     451 (4.4%)              450 (4.3%)              434 (4.2%)                      {txt}{c |}
  {c |} {res}   No                                7,656 (24.7%)    2,543 (24.5%)           2,555 (24.6%)           2,558 (24.9%)                   {txt}{c |}
  {c |} {res}   Missing                           22,003 (71.0%)   7,365 (71.1%)           7,376 (71.1%)           7,262 (70.8%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 6 months                                                                                                   0.45   {txt}{c |}
  {c |} {res}   Yes                               561 (1.8%)       193 (1.9%)              188 (1.8%)              180 (1.8%)                      {txt}{c |}
  {c |} {res}   No                                3,488 (11.3%)    1,112 (10.7%)           1,186 (11.4%)           1,190 (11.6%)                   {txt}{c |}
  {c |} {res}   Missing                           26,945 (86.9%)   9,054 (87.4%)           9,007 (86.8%)           8,884 (86.6%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 6 months                                                                                                  0.94   {txt}{c |}
  {c |} {res}   Yes                               268 (0.9%)       91 (0.9%)               93 (0.9%)               84 (0.8%)                       {txt}{c |}
  {c |} {res}   No                                1,900 (6.1%)     647 (6.2%)              640 (6.2%)              613 (6.0%)                      {txt}{c |}
  {c |} {res}   Missing                           28,826 (93.0%)   9,621 (92.9%)           9,648 (92.9%)           9,557 (93.2%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months                                                                                             0.78   {txt}{c |}
  {c |} {res}   Yes                               296 (1.0%)       108 (1.0%)              92 (0.9%)               96 (0.9%)                       {txt}{c |}
  {c |} {res}   No                                1,886 (6.1%)     651 (6.3%)              615 (5.9%)              620 (6.0%)                      {txt}{c |}
  {c |} {res}   Missing                           28,812 (93.0%)   9,600 (92.7%)           9,674 (93.2%)           9,538 (93.0%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 6 months                                                                                                    0.54   {txt}{c |}
  {c |} {res}   Yes                               252 (0.8%)       76 (0.7%)               88 (0.8%)               88 (0.9%)                       {txt}{c |}
  {c |} {res}   No                                1,880 (6.1%)     629 (6.1%)              608 (5.9%)              643 (6.3%)                      {txt}{c |}
  {c |} {res}   Missing                           28,862 (93.1%)   9,654 (93.2%)           9,685 (93.3%)           9,523 (92.9%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months                                                                                                 0.90   {txt}{c |}
  {c |} {res}   Yes                               4,007 (12.9%)    1,341 (12.9%)           1,359 (13.1%)           1,307 (12.7%)                   {txt}{c |}
  {c |} {res}   No                                14,557 (47.0%)   4,824 (46.6%)           4,938 (47.6%)           4,795 (46.8%)                   {txt}{c |}
  {c |} {res}   Missing                           12,430 (40.1%)   4,194 (40.5%)           4,084 (39.3%)           4,152 (40.5%)                   {txt}{c |}
  {c BLC}{hline 36}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Drug prescription table at 12 months, for those with at least 12m registration, by all patients year of diagnosis
. preserve
{txt}
{com}. keep if has_12m_follow_up==1
{txt}(3,405 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_12m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                   N_T     N_1     N_2     N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 12 months              29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 12 months         29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 12 months        29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months   29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 12 months          29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months       29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                      Total            March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                      N=29,371         N=9,834                 N=9,800                 N=9,737                         {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 12 months                                                                                                        0.38   {txt}{c |}
  {c |} {res}   Yes                                2,813 (9.6%)     957 (9.7%)              911 (9.3%)              945 (9.7%)                      {txt}{c |}
  {c |} {res}   No                                 5,706 (19.4%)    1,890 (19.2%)           1,933 (19.7%)           1,883 (19.3%)                   {txt}{c |}
  {c |} {res}   Missing                            20,852 (71.0%)   6,987 (71.0%)           6,956 (71.0%)           6,909 (71.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 12 months                                                                                                   0.15   {txt}{c |}
  {c |} {res}   Yes                                1,197 (4.1%)     406 (4.1%)              383 (3.9%)              408 (4.2%)                      {txt}{c |}
  {c |} {res}   No                                 2,640 (9.0%)     834 (8.5%)              926 (9.4%)              880 (9.0%)                      {txt}{c |}
  {c |} {res}   Missing                            25,534 (86.9%)   8,594 (87.4%)           8,491 (86.6%)           8,449 (86.8%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 12 months                                                                                                  0.45   {txt}{c |}
  {c |} {res}   Yes                                583 (2.0%)       210 (2.1%)              197 (2.0%)              176 (1.8%)                      {txt}{c |}
  {c |} {res}   No                                 1,459 (5.0%)     494 (5.0%)              484 (4.9%)              481 (4.9%)                      {txt}{c |}
  {c |} {res}   Missing                            27,329 (93.0%)   9,130 (92.8%)           9,119 (93.1%)           9,080 (93.3%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months                                                                                             0.82   {txt}{c |}
  {c |} {res}   Yes                                623 (2.1%)       212 (2.2%)              198 (2.0%)              213 (2.2%)                      {txt}{c |}
  {c |} {res}   No                                 1,452 (4.9%)     495 (5.0%)              479 (4.9%)              478 (4.9%)                      {txt}{c |}
  {c |} {res}   Missing                            27,296 (92.9%)   9,127 (92.8%)           9,123 (93.1%)           9,046 (92.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 12 months                                                                                                    0.51   {txt}{c |}
  {c |} {res}   Yes                                565 (1.9%)       181 (1.8%)              180 (1.8%)              204 (2.1%)                      {txt}{c |}
  {c |} {res}   No                                 1,460 (5.0%)     494 (5.0%)              478 (4.9%)              488 (5.0%)                      {txt}{c |}
  {c |} {res}   Missing                            27,346 (93.1%)   9,159 (93.1%)           9,142 (93.3%)           9,045 (92.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months                                                                                                 0.26   {txt}{c |}
  {c |} {res}   Yes                                7,982 (27.2%)    2,681 (27.3%)           2,665 (27.2%)           2,636 (27.1%)                   {txt}{c |}
  {c |} {res}   No                                 9,614 (32.7%)    3,178 (32.3%)           3,323 (33.9%)           3,113 (32.0%)                   {txt}{c |}
  {c |} {res}   Missing                            11,775 (40.1%)   3,975 (40.4%)           3,812 (38.9%)           3,988 (41.0%)                   {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Drug prescription table at 6 and 12 months, for those with at least 12m registration, by all patients year of diagnosis
. preserve
{txt}
{com}. keep if has_12m_follow_up==1
{txt}(3,405 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  csdmard_12m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                   N_T     N_1     N_2     N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 6 months               29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 12 months              29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 6 months          29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 12 months         29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 6 months         29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 12 months        29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months    29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months   29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 6 months           29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 12 months          29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months        29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months       29,371   9,834   9,800   9,737     0     0     0     0 {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                      Total            March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                      N=29,371         N=9,834                 N=9,800                 N=9,737                         {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 6 months                                                                                                         0.89   {txt}{c |}
  {c |} {res}   Yes                                1,259 (4.3%)     428 (4.4%)              418 (4.3%)              413 (4.2%)                      {txt}{c |}
  {c |} {res}   No                                 7,260 (24.7%)    2,419 (24.6%)           2,426 (24.8%)           2,415 (24.8%)                   {txt}{c |}
  {c |} {res}   Missing                            20,852 (71.0%)   6,987 (71.0%)           6,956 (71.0%)           6,909 (71.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 12 months                                                                                                        0.38   {txt}{c |}
  {c |} {res}   Yes                                2,813 (9.6%)     957 (9.7%)              911 (9.3%)              945 (9.7%)                      {txt}{c |}
  {c |} {res}   No                                 5,706 (19.4%)    1,890 (19.2%)           1,933 (19.7%)           1,883 (19.3%)                   {txt}{c |}
  {c |} {res}   Missing                            20,852 (71.0%)   6,987 (71.0%)           6,956 (71.0%)           6,909 (71.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 6 months                                                                                                    0.32   {txt}{c |}
  {c |} {res}   Yes                                530 (1.8%)       186 (1.9%)              176 (1.8%)              168 (1.7%)                      {txt}{c |}
  {c |} {res}   No                                 3,307 (11.3%)    1,054 (10.7%)           1,133 (11.6%)           1,120 (11.5%)                   {txt}{c |}
  {c |} {res}   Missing                            25,534 (86.9%)   8,594 (87.4%)           8,491 (86.6%)           8,449 (86.8%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 12 months                                                                                                   0.15   {txt}{c |}
  {c |} {res}   Yes                                1,197 (4.1%)     406 (4.1%)              383 (3.9%)              408 (4.2%)                      {txt}{c |}
  {c |} {res}   No                                 2,640 (9.0%)     834 (8.5%)              926 (9.4%)              880 (9.0%)                      {txt}{c |}
  {c |} {res}   Missing                            25,534 (86.9%)   8,594 (87.4%)           8,491 (86.6%)           8,449 (86.8%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 6 months                                                                                                   0.99   {txt}{c |}
  {c |} {res}   Yes                                246 (0.8%)       84 (0.9%)               83 (0.8%)               79 (0.8%)                       {txt}{c |}
  {c |} {res}   No                                 1,796 (6.1%)     620 (6.3%)              598 (6.1%)              578 (5.9%)                      {txt}{c |}
  {c |} {res}   Missing                            27,329 (93.0%)   9,130 (92.8%)           9,119 (93.1%)           9,080 (93.3%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 12 months                                                                                                  0.45   {txt}{c |}
  {c |} {res}   Yes                                583 (2.0%)       210 (2.1%)              197 (2.0%)              176 (1.8%)                      {txt}{c |}
  {c |} {res}   No                                 1,459 (5.0%)     494 (5.0%)              484 (4.9%)              481 (4.9%)                      {txt}{c |}
  {c |} {res}   Missing                            27,329 (93.0%)   9,130 (92.8%)           9,119 (93.1%)           9,080 (93.3%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months                                                                                              0.78   {txt}{c |}
  {c |} {res}   Yes                                281 (1.0%)       100 (1.0%)              87 (0.9%)               94 (1.0%)                       {txt}{c |}
  {c |} {res}   No                                 1,794 (6.1%)     607 (6.2%)              590 (6.0%)              597 (6.1%)                      {txt}{c |}
  {c |} {res}   Missing                            27,296 (92.9%)   9,127 (92.8%)           9,123 (93.1%)           9,046 (92.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months                                                                                             0.82   {txt}{c |}
  {c |} {res}   Yes                                623 (2.1%)       212 (2.2%)              198 (2.0%)              213 (2.2%)                      {txt}{c |}
  {c |} {res}   No                                 1,452 (4.9%)     495 (5.0%)              479 (4.9%)              478 (4.9%)                      {txt}{c |}
  {c |} {res}   Missing                            27,296 (92.9%)   9,127 (92.8%)           9,123 (93.1%)           9,046 (92.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 6 months                                                                                                     0.52   {txt}{c |}
  {c |} {res}   Yes                                242 (0.8%)       73 (0.7%)               81 (0.8%)               88 (0.9%)                       {txt}{c |}
  {c |} {res}   No                                 1,783 (6.1%)     602 (6.1%)              577 (5.9%)              604 (6.2%)                      {txt}{c |}
  {c |} {res}   Missing                            27,346 (93.1%)   9,159 (93.1%)           9,142 (93.3%)           9,045 (92.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 12 months                                                                                                    0.51   {txt}{c |}
  {c |} {res}   Yes                                565 (1.9%)       181 (1.8%)              180 (1.8%)              204 (2.1%)                      {txt}{c |}
  {c |} {res}   No                                 1,460 (5.0%)     494 (5.0%)              478 (4.9%)              488 (5.0%)                      {txt}{c |}
  {c |} {res}   Missing                            27,346 (93.1%)   9,159 (93.1%)           9,142 (93.3%)           9,045 (92.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months                                                                                                  0.93   {txt}{c |}
  {c |} {res}   Yes                                3,816 (13.0%)    1,280 (13.0%)           1,296 (13.2%)           1,240 (12.7%)                   {txt}{c |}
  {c |} {res}   No                                 13,780 (46.9%)   4,579 (46.6%)           4,692 (47.9%)           4,509 (46.3%)                   {txt}{c |}
  {c |} {res}   Missing                            11,775 (40.1%)   3,975 (40.4%)           3,812 (38.9%)           3,988 (41.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months                                                                                                 0.26   {txt}{c |}
  {c |} {res}   Yes                                7,982 (27.2%)    2,681 (27.3%)           2,665 (27.2%)           2,636 (27.1%)                   {txt}{c |}
  {c |} {res}   No                                 9,614 (32.7%)    3,178 (32.3%)           3,323 (33.9%)           3,113 (32.0%)                   {txt}{c |}
  {c |} {res}   Missing                            11,775 (40.1%)   3,975 (40.4%)           3,812 (38.9%)           3,988 (41.0%)                   {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 16}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Drug prescription table at 6 months, for those with at least 6m registration, for RA patients by year of diagnosis
. preserve
{txt}
{com}. keep if has_6m_follow_up==1 & ra_code==1
{txt}(23,392 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                  N_T     N_1     N_2     N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 6 months              10,239   3,415   3,356   3,468     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 6 months         10,239   3,415   3,356   3,468     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 6 months        10,239   3,415   3,356   3,468     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months   10,239   3,415   3,356   3,468     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 6 months          10,239   3,415   3,356   3,468     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months       10,239   3,415   3,356   3,468     0     0     0     0 {txt}{c |}
  {c BLC}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                     Total           March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                     N=10,239        N=3,415                 N=3,356                 N=3,468                         {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 6 months                                                                                                       0.90   {txt}{c |}
  {c |} {res}   Yes                               447 (4.4%)      147 (4.3%)              149 (4.4%)              151 (4.4%)                      {txt}{c |}
  {c |} {res}   No                                2,550 (24.9%)   820 (24.0%)             841 (25.1%)             889 (25.6%)                     {txt}{c |}
  {c |} {res}   Missing                           7,242 (70.7%)   2,448 (71.7%)           2,366 (70.5%)           2,428 (70.0%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 6 months                                                                                                  0.33   {txt}{c |}
  {c |} {res}   Yes                               184 (1.8%)      65 (1.9%)               62 (1.8%)               57 (1.6%)                       {txt}{c |}
  {c |} {res}   No                                1,189 (11.6%)   360 (10.5%)             408 (12.2%)             421 (12.1%)                     {txt}{c |}
  {c |} {res}   Missing                           8,866 (86.6%)   2,990 (87.6%)           2,886 (86.0%)           2,990 (86.2%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 6 months                                                                                                 0.80   {txt}{c |}
  {c |} {res}   Yes                               86 (0.8%)       27 (0.8%)               28 (0.8%)               31 (0.9%)                       {txt}{c |}
  {c |} {res}   No                                632 (6.2%)      211 (6.2%)              216 (6.4%)              205 (5.9%)                      {txt}{c |}
  {c |} {res}   Missing                           9,521 (93.0%)   3,177 (93.0%)           3,112 (92.7%)           3,232 (93.2%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months                                                                                            0.94   {txt}{c |}
  {c |} {res}   Yes                               106 (1.0%)      38 (1.1%)               30 (0.9%)               38 (1.1%)                       {txt}{c |}
  {c |} {res}   No                                628 (6.1%)      220 (6.4%)              188 (5.6%)              220 (6.3%)                      {txt}{c |}
  {c |} {res}   Missing                           9,505 (92.8%)   3,157 (92.4%)           3,138 (93.5%)           3,210 (92.6%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 6 months                                                                                                   0.19   {txt}{c |}
  {c |} {res}   Yes                               84 (0.8%)       23 (0.7%)               34 (1.0%)               27 (0.8%)                       {txt}{c |}
  {c |} {res}   No                                628 (6.1%)      209 (6.1%)              193 (5.8%)              226 (6.5%)                      {txt}{c |}
  {c |} {res}   Missing                           9,527 (93.0%)   3,183 (93.2%)           3,129 (93.2%)           3,215 (92.7%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months                                                                                                0.76   {txt}{c |}
  {c |} {res}   Yes                               1,307 (12.8%)   440 (12.9%)             437 (13.0%)             430 (12.4%)                     {txt}{c |}
  {c |} {res}   No                                4,808 (47.0%)   1,592 (46.6%)           1,582 (47.1%)           1,634 (47.1%)                   {txt}{c |}
  {c |} {res}   Missing                           4,124 (40.3%)   1,383 (40.5%)           1,337 (39.8%)           1,404 (40.5%)                   {txt}{c |}
  {c BLC}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
. *Drug prescription table at 12 months, for those with at least 12m registration, by RA patients year of diagnosis
. preserve
{txt}
{com}. keep if has_12m_follow_up==1 & ra_code==1
{txt}(23,851 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_12m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                  N_T     N_1     N_2     N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 12 months              9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 12 months         9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 12 months        9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months   9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 12 months          9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months       9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                      Total           March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                      N=9,802         N=3,310                 N=3,168                 N=3,324                         {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 12 months                                                                                                       0.62   {txt}{c |}
  {c |} {res}   Yes                                944 (9.6%)      309 (9.3%)              296 (9.3%)              339 (10.2%)                     {txt}{c |}
  {c |} {res}   No                                 1,922 (19.6%)   632 (19.1%)             632 (19.9%)             658 (19.8%)                     {txt}{c |}
  {c |} {res}   Missing                            6,936 (70.8%)   2,369 (71.6%)           2,240 (70.7%)           2,327 (70.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 12 months                                                                                                  0.15   {txt}{c |}
  {c |} {res}   Yes                                411 (4.2%)      146 (4.4%)              126 (4.0%)              139 (4.2%)                      {txt}{c |}
  {c |} {res}   No                                 901 (9.2%)      274 (8.3%)              314 (9.9%)              313 (9.4%)                      {txt}{c |}
  {c |} {res}   Missing                            8,490 (86.6%)   2,890 (87.3%)           2,728 (86.1%)           2,872 (86.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 12 months                                                                                                 0.92   {txt}{c |}
  {c |} {res}   Yes                                185 (1.9%)      61 (1.8%)               64 (2.0%)               60 (1.8%)                       {txt}{c |}
  {c |} {res}   No                                 497 (5.1%)      170 (5.1%)              164 (5.2%)              163 (4.9%)                      {txt}{c |}
  {c |} {res}   Missing                            9,120 (93.0%)   3,079 (93.0%)           2,940 (92.8%)           3,101 (93.3%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months                                                                                            0.51   {txt}{c |}
  {c |} {res}   Yes                                216 (2.2%)      68 (2.1%)               64 (2.0%)               84 (2.5%)                       {txt}{c |}
  {c |} {res}   No                                 476 (4.9%)      171 (5.2%)              135 (4.3%)              170 (5.1%)                      {txt}{c |}
  {c |} {res}   Missing                            9,110 (92.9%)   3,071 (92.8%)           2,969 (93.7%)           3,070 (92.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 12 months                                                                                                   0.25   {txt}{c |}
  {c |} {res}   Yes                                187 (1.9%)      55 (1.7%)               57 (1.8%)               75 (2.3%)                       {txt}{c |}
  {c |} {res}   No                                 501 (5.1%)      172 (5.2%)              161 (5.1%)              168 (5.1%)                      {txt}{c |}
  {c |} {res}   Missing                            9,114 (93.0%)   3,083 (93.1%)           2,950 (93.1%)           3,081 (92.7%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months                                                                                                0.18   {txt}{c |}
  {c |} {res}   Yes                                2,658 (27.1%)   880 (26.6%)             851 (26.9%)             927 (27.9%)                     {txt}{c |}
  {c |} {res}   No                                 3,202 (32.7%)   1,083 (32.7%)           1,074 (33.9%)           1,045 (31.4%)                   {txt}{c |}
  {c |} {res}   Missing                            3,942 (40.2%)   1,347 (40.7%)           1,243 (39.2%)           1,352 (40.7%)                   {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
. *Drug prescription table at 6 and 12 months, for those with at least 12m registration, by RA patients year of diagnosis
. preserve
{txt}
{com}. keep if has_12m_follow_up==1 & ra_code==1
{txt}(23,851 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  csdmard_12m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                  N_T     N_1     N_2     N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 6 months               9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 12 months              9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 6 months          9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 12 months         9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 6 months         9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 12 months        9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months    9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months   9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 6 months           9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 12 months          9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months        9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months       9,802   3,310   3,168   3,324     0     0     0     0 {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                      Total           March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                      N=9,802         N=3,310                 N=3,168                 N=3,324                         {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 6 months                                                                                                        0.90   {txt}{c |}
  {c |} {res}   Yes                                424 (4.3%)      136 (4.1%)              141 (4.5%)              147 (4.4%)                      {txt}{c |}
  {c |} {res}   No                                 2,442 (24.9%)   805 (24.3%)             787 (24.8%)             850 (25.6%)                     {txt}{c |}
  {c |} {res}   Missing                            6,936 (70.8%)   2,369 (71.6%)           2,240 (70.7%)           2,327 (70.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 12 months                                                                                                       0.62   {txt}{c |}
  {c |} {res}   Yes                                944 (9.6%)      309 (9.3%)              296 (9.3%)              339 (10.2%)                     {txt}{c |}
  {c |} {res}   No                                 1,922 (19.6%)   632 (19.1%)             632 (19.9%)             658 (19.8%)                     {txt}{c |}
  {c |} {res}   Missing                            6,936 (70.8%)   2,369 (71.6%)           2,240 (70.7%)           2,327 (70.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 6 months                                                                                                   0.29   {txt}{c |}
  {c |} {res}   Yes                                178 (1.8%)      66 (2.0%)               56 (1.8%)               56 (1.7%)                       {txt}{c |}
  {c |} {res}   No                                 1,134 (11.6%)   354 (10.7%)             384 (12.1%)             396 (11.9%)                     {txt}{c |}
  {c |} {res}   Missing                            8,490 (86.6%)   2,890 (87.3%)           2,728 (86.1%)           2,872 (86.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 12 months                                                                                                  0.15   {txt}{c |}
  {c |} {res}   Yes                                411 (4.2%)      146 (4.4%)              126 (4.0%)              139 (4.2%)                      {txt}{c |}
  {c |} {res}   No                                 901 (9.2%)      274 (8.3%)              314 (9.9%)              313 (9.4%)                      {txt}{c |}
  {c |} {res}   Missing                            8,490 (86.6%)   2,890 (87.3%)           2,728 (86.1%)           2,872 (86.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 6 months                                                                                                  0.96   {txt}{c |}
  {c |} {res}   Yes                                73 (0.7%)       24 (0.7%)               24 (0.8%)               25 (0.8%)                       {txt}{c |}
  {c |} {res}   No                                 609 (6.2%)      207 (6.3%)              204 (6.4%)              198 (6.0%)                      {txt}{c |}
  {c |} {res}   Missing                            9,120 (93.0%)   3,079 (93.0%)           2,940 (92.8%)           3,101 (93.3%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 12 months                                                                                                 0.92   {txt}{c |}
  {c |} {res}   Yes                                185 (1.9%)      61 (1.8%)               64 (2.0%)               60 (1.8%)                       {txt}{c |}
  {c |} {res}   No                                 497 (5.1%)      170 (5.1%)              164 (5.2%)              163 (4.9%)                      {txt}{c |}
  {c |} {res}   Missing                            9,120 (93.0%)   3,079 (93.0%)           2,940 (92.8%)           3,101 (93.3%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months                                                                                             0.81   {txt}{c |}
  {c |} {res}   Yes                                100 (1.0%)      32 (1.0%)               31 (1.0%)               37 (1.1%)                       {txt}{c |}
  {c |} {res}   No                                 592 (6.0%)      207 (6.3%)              168 (5.3%)              217 (6.5%)                      {txt}{c |}
  {c |} {res}   Missing                            9,110 (92.9%)   3,071 (92.8%)           2,969 (93.7%)           3,070 (92.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months                                                                                            0.51   {txt}{c |}
  {c |} {res}   Yes                                216 (2.2%)      68 (2.1%)               64 (2.0%)               84 (2.5%)                       {txt}{c |}
  {c |} {res}   No                                 476 (4.9%)      171 (5.2%)              135 (4.3%)              170 (5.1%)                      {txt}{c |}
  {c |} {res}   Missing                            9,110 (92.9%)   3,071 (92.8%)           2,969 (93.7%)           3,070 (92.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 6 months                                                                                                    0.063  {txt}{c |}
  {c |} {res}   Yes                                84 (0.9%)       19 (0.6%)               34 (1.1%)               31 (0.9%)                       {txt}{c |}
  {c |} {res}   No                                 604 (6.2%)      208 (6.3%)              184 (5.8%)              212 (6.4%)                      {txt}{c |}
  {c |} {res}   Missing                            9,114 (93.0%)   3,083 (93.1%)           2,950 (93.1%)           3,081 (92.7%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 12 months                                                                                                   0.25   {txt}{c |}
  {c |} {res}   Yes                                187 (1.9%)      55 (1.7%)               57 (1.8%)               75 (2.3%)                       {txt}{c |}
  {c |} {res}   No                                 501 (5.1%)      172 (5.2%)              161 (5.1%)              168 (5.1%)                      {txt}{c |}
  {c |} {res}   Missing                            9,114 (93.0%)   3,083 (93.1%)           2,950 (93.1%)           3,081 (92.7%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months                                                                                                 0.91   {txt}{c |}
  {c |} {res}   Yes                                1,228 (12.5%)   414 (12.5%)             407 (12.8%)             407 (12.2%)                     {txt}{c |}
  {c |} {res}   No                                 4,632 (47.3%)   1,549 (46.8%)           1,518 (47.9%)           1,565 (47.1%)                   {txt}{c |}
  {c |} {res}   Missing                            3,942 (40.2%)   1,347 (40.7%)           1,243 (39.2%)           1,352 (40.7%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months                                                                                                0.18   {txt}{c |}
  {c |} {res}   Yes                                2,658 (27.1%)   880 (26.6%)             851 (26.9%)             927 (27.9%)                     {txt}{c |}
  {c |} {res}   No                                 3,202 (32.7%)   1,083 (32.7%)           1,074 (33.9%)           1,045 (31.4%)                   {txt}{c |}
  {c |} {res}   Missing                            3,942 (40.2%)   1,347 (40.7%)           1,243 (39.2%)           1,352 (40.7%)                   {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. *Drug prescription table at 6 months, for those with at least 6m registration, for PsA patients by year of diagnosis
. preserve
{txt}
{com}. keep if has_6m_follow_up==1 & psa_code==1
{txt}(23,354 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m bin %3.1f \ ///
>                  ) clear
{res}{err}bin variable biologic_6m must be 0 (negative) or 1 (positive)
{txt}{search r(198), local:r(198);}

end of do-file

{search r(198), local:r(198);}

{com}. do "C:\Users\k1754142\AppData\Local\Temp\STDb4c_000000.tmp"
{txt}
{com}. preserve
{txt}
{com}. keep if has_6m_follow_up==1 & psa_code==1
{txt}(23,354 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                  N_T     N_1     N_2     N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 6 months              10,259   3,442   3,414   3,403     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 6 months         10,259   3,442   3,414   3,403     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 6 months        10,259   3,442   3,414   3,403     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months   10,259   3,442   3,414   3,403     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 6 months          10,259   3,442   3,414   3,403     0     0     0     0 {txt}{c |}
  {c LT}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months       10,259   3,442   3,414   3,403     0     0     0     0 {txt}{c |}
  {c BLC}{hline 36}{c -}{hline 8}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                     Total           March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                     N=10,259        N=3,442                 N=3,414                 N=3,403                         {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 6 months                                                                                                       0.34   {txt}{c |}
  {c |} {res}   Yes                               423 (4.1%)      155 (4.5%)              141 (4.1%)              127 (3.7%)                      {txt}{c |}
  {c |} {res}   No                                2,520 (24.6%)   855 (24.8%)             821 (24.0%)             844 (24.8%)                     {txt}{c |}
  {c |} {res}   Missing                           7,316 (71.3%)   2,432 (70.7%)           2,452 (71.8%)           2,432 (71.5%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 6 months                                                                                                  0.60   {txt}{c |}
  {c |} {res}   Yes                               173 (1.7%)      64 (1.9%)               55 (1.6%)               54 (1.6%)                       {txt}{c |}
  {c |} {res}   No                                1,139 (11.1%)   377 (11.0%)             386 (11.3%)             376 (11.0%)                     {txt}{c |}
  {c |} {res}   Missing                           8,947 (87.2%)   3,001 (87.2%)           2,973 (87.1%)           2,973 (87.4%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 6 months                                                                                                 0.16   {txt}{c |}
  {c |} {res}   Yes                               90 (0.9%)       39 (1.1%)               28 (0.8%)               23 (0.7%)                       {txt}{c |}
  {c |} {res}   No                                646 (6.3%)      219 (6.4%)              209 (6.1%)              218 (6.4%)                      {txt}{c |}
  {c |} {res}   Missing                           9,523 (92.8%)   3,184 (92.5%)           3,177 (93.1%)           3,162 (92.9%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months                                                                                            0.60   {txt}{c |}
  {c |} {res}   Yes                               97 (0.9%)       33 (1.0%)               36 (1.1%)               28 (0.8%)                       {txt}{c |}
  {c |} {res}   No                                596 (5.8%)      213 (6.2%)              191 (5.6%)              192 (5.6%)                      {txt}{c |}
  {c |} {res}   Missing                           9,566 (93.2%)   3,196 (92.9%)           3,187 (93.4%)           3,183 (93.5%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 6 months                                                                                                   0.79   {txt}{c |}
  {c |} {res}   Yes                               79 (0.8%)       25 (0.7%)               27 (0.8%)               27 (0.8%)                       {txt}{c |}
  {c |} {res}   No                                601 (5.9%)      208 (6.0%)              184 (5.4%)              209 (6.1%)                      {txt}{c |}
  {c |} {res}   Missing                           9,579 (93.4%)   3,209 (93.2%)           3,203 (93.8%)           3,167 (93.1%)                   {txt}{c |}
  {c LT}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months                                                                                                0.14   {txt}{c |}
  {c |} {res}   Yes                               1,314 (12.8%)   416 (12.1%)             430 (12.6%)             468 (13.8%)                     {txt}{c |}
  {c |} {res}   No                                4,845 (47.2%)   1,627 (47.3%)           1,631 (47.8%)           1,587 (46.6%)                   {txt}{c |}
  {c |} {res}   Missing                           4,100 (40.0%)   1,399 (40.6%)           1,353 (39.6%)           1,348 (39.6%)                   {txt}{c |}
  {c BLC}{hline 36}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
. *Drug prescription table at 12 months, for those with at least 12m registration, by PsA patients year of diagnosis
. preserve
{txt}
{com}. keep if has_12m_follow_up==1 & psa_code==1
{txt}(23,956 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_12m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                  N_T     N_1     N_2     N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 12 months              9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 12 months         9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 12 months        9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months   9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 12 months          9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months       9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                      Total           March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                      N=9,678         N=3,237                 N=3,227                 N=3,214                         {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 12 months                                                                                                       0.38   {txt}{c |}
  {c |} {res}   Yes                                888 (9.2%)      319 (9.9%)              288 (8.9%)              281 (8.7%)                      {txt}{c |}
  {c |} {res}   No                                 1,878 (19.4%)   624 (19.3%)             632 (19.6%)             622 (19.4%)                     {txt}{c |}
  {c |} {res}   Missing                            6,912 (71.4%)   2,294 (70.9%)           2,307 (71.5%)           2,311 (71.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 12 months                                                                                                  0.58   {txt}{c |}
  {c |} {res}   Yes                                380 (3.9%)      128 (4.0%)              124 (3.8%)              128 (4.0%)                      {txt}{c |}
  {c |} {res}   No                                 855 (8.8%)      282 (8.7%)              304 (9.4%)              269 (8.4%)                      {txt}{c |}
  {c |} {res}   Missing                            8,443 (87.2%)   2,827 (87.3%)           2,799 (86.7%)           2,817 (87.6%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 12 months                                                                                                 0.091  {txt}{c |}
  {c |} {res}   Yes                                185 (1.9%)      76 (2.3%)               57 (1.8%)               52 (1.6%)                       {txt}{c |}
  {c |} {res}   No                                 503 (5.2%)      163 (5.0%)              167 (5.2%)              173 (5.4%)                      {txt}{c |}
  {c |} {res}   Missing                            8,990 (92.9%)   2,998 (92.6%)           3,003 (93.1%)           2,989 (93.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months                                                                                            0.83   {txt}{c |}
  {c |} {res}   Yes                                200 (2.1%)      72 (2.2%)               67 (2.1%)               61 (1.9%)                       {txt}{c |}
  {c |} {res}   No                                 458 (4.7%)      156 (4.8%)              152 (4.7%)              150 (4.7%)                      {txt}{c |}
  {c |} {res}   Missing                            9,020 (93.2%)   3,009 (93.0%)           3,008 (93.2%)           3,003 (93.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 12 months                                                                                                   0.88   {txt}{c |}
  {c |} {res}   Yes                                168 (1.7%)      58 (1.8%)               55 (1.7%)               55 (1.7%)                       {txt}{c |}
  {c |} {res}   No                                 467 (4.8%)      160 (4.9%)              145 (4.5%)              162 (5.0%)                      {txt}{c |}
  {c |} {res}   Missing                            9,043 (93.4%)   3,019 (93.3%)           3,027 (93.8%)           2,997 (93.2%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months                                                                                                0.13   {txt}{c |}
  {c |} {res}   Yes                                2,633 (27.2%)   860 (26.6%)             867 (26.9%)             906 (28.2%)                     {txt}{c |}
  {c |} {res}   No                                 3,151 (32.6%)   1,055 (32.6%)           1,089 (33.7%)           1,007 (31.3%)                   {txt}{c |}
  {c |} {res}   Missing                            3,894 (40.2%)   1,322 (40.8%)           1,271 (39.4%)           1,301 (40.5%)                   {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
. *Drug prescription table at 6 and 12 months, for those with at least 12m registration, by PsA patients year of diagnosis
. preserve
{txt}
{com}. keep if has_12m_follow_up==1 & psa_code==1
{txt}(23,956 observations deleted)

{com}. table1_mc, by(diagnosis_year) total(before) onecol missing nospacelowpercent iqrmiddle(",")  ///
>         vars(csdmard_6m cat %3.1f \ ///
>                  csdmard_12m cat %3.1f \ ///
>                  mtx_6m cat %3.1f \ ///
>                  mtx_12m cat %3.1f \ ///
>                  ssz_6m cat %3.1f \ ///
>                  ssz_12m cat %3.1f \ ///
>                  hcq_6m cat %3.1f \ ///
>                  hcq_12m cat %3.1f \ ///
>                  lef_6m cat %3.1f \ ///
>                  lef_12m cat %3.1f \ ///
>                  biologic_6m cat %3.1f \ ///
>                  biologic_12m cat %3.1f \ ///
>                  ) clear
{res}{txt}
  {c TLC}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c TRC}
  {c |} {res}factor                                  N_T     N_1     N_2     N_3   m_T   m_1   m_2   m_3 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 6 months               9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}csDMARD within 12 months              9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 6 months          9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Methotrexate within 12 months         9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 6 months         9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Sulfasalazine within 12 months        9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months    9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months   9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 6 months           9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}Leflunomide within 12 months          9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months        9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c LT}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months       9,678   3,237   3,227   3,214     0     0     0     0 {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 7}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c -}{hline 5}{c BRC}
   N_ ... #records used below,   m_ ... #records not used
 
  {c TLC}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c TRC}
  {c |} {res}                                      Total           March 2019-March 2020   March 2020-March 2021   March 2021-March 2022   p-value {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}                                      N=9,678         N=3,237                 N=3,227                 N=3,214                         {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 6 months                                                                                                        0.55   {txt}{c |}
  {c |} {res}   Yes                                394 (4.1%)      143 (4.4%)              130 (4.0%)              121 (3.8%)                      {txt}{c |}
  {c |} {res}   No                                 2,372 (24.5%)   800 (24.7%)             790 (24.5%)             782 (24.3%)                     {txt}{c |}
  {c |} {res}   Missing                            6,912 (71.4%)   2,294 (70.9%)           2,307 (71.5%)           2,311 (71.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}csDMARD within 12 months                                                                                                       0.38   {txt}{c |}
  {c |} {res}   Yes                                888 (9.2%)      319 (9.9%)              288 (8.9%)              281 (8.7%)                      {txt}{c |}
  {c |} {res}   No                                 1,878 (19.4%)   624 (19.3%)             632 (19.6%)             622 (19.4%)                     {txt}{c |}
  {c |} {res}   Missing                            6,912 (71.4%)   2,294 (70.9%)           2,307 (71.5%)           2,311 (71.9%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 6 months                                                                                                   0.83   {txt}{c |}
  {c |} {res}   Yes                                163 (1.7%)      56 (1.7%)               53 (1.6%)               54 (1.7%)                       {txt}{c |}
  {c |} {res}   No                                 1,072 (11.1%)   354 (10.9%)             375 (11.6%)             343 (10.7%)                     {txt}{c |}
  {c |} {res}   Missing                            8,443 (87.2%)   2,827 (87.3%)           2,799 (86.7%)           2,817 (87.6%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Methotrexate within 12 months                                                                                                  0.58   {txt}{c |}
  {c |} {res}   Yes                                380 (3.9%)      128 (4.0%)              124 (3.8%)              128 (4.0%)                      {txt}{c |}
  {c |} {res}   No                                 855 (8.8%)      282 (8.7%)              304 (9.4%)              269 (8.4%)                      {txt}{c |}
  {c |} {res}   Missing                            8,443 (87.2%)   2,827 (87.3%)           2,799 (86.7%)           2,817 (87.6%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 6 months                                                                                                  0.39   {txt}{c |}
  {c |} {res}   Yes                                85 (0.9%)       35 (1.1%)               26 (0.8%)               24 (0.7%)                       {txt}{c |}
  {c |} {res}   No                                 603 (6.2%)      204 (6.3%)              198 (6.1%)              201 (6.3%)                      {txt}{c |}
  {c |} {res}   Missing                            8,990 (92.9%)   2,998 (92.6%)           3,003 (93.1%)           2,989 (93.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Sulfasalazine within 12 months                                                                                                 0.091  {txt}{c |}
  {c |} {res}   Yes                                185 (1.9%)      76 (2.3%)               57 (1.8%)               52 (1.6%)                       {txt}{c |}
  {c |} {res}   No                                 503 (5.2%)      163 (5.0%)              167 (5.2%)              173 (5.4%)                      {txt}{c |}
  {c |} {res}   Missing                            8,990 (92.9%)   2,998 (92.6%)           3,003 (93.1%)           2,989 (93.0%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 6 months                                                                                             0.79   {txt}{c |}
  {c |} {res}   Yes                                92 (1.0%)       32 (1.0%)               33 (1.0%)               27 (0.8%)                       {txt}{c |}
  {c |} {res}   No                                 566 (5.8%)      196 (6.1%)              186 (5.8%)              184 (5.7%)                      {txt}{c |}
  {c |} {res}   Missing                            9,020 (93.2%)   3,009 (93.0%)           3,008 (93.2%)           3,003 (93.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Hydroxychloroquine within 12 months                                                                                            0.83   {txt}{c |}
  {c |} {res}   Yes                                200 (2.1%)      72 (2.2%)               67 (2.1%)               61 (1.9%)                       {txt}{c |}
  {c |} {res}   No                                 458 (4.7%)      156 (4.8%)              152 (4.7%)              150 (4.7%)                      {txt}{c |}
  {c |} {res}   Missing                            9,020 (93.2%)   3,009 (93.0%)           3,008 (93.2%)           3,003 (93.4%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 6 months                                                                                                    0.84   {txt}{c |}
  {c |} {res}   Yes                                70 (0.7%)       26 (0.8%)               22 (0.7%)               22 (0.7%)                       {txt}{c |}
  {c |} {res}   No                                 565 (5.8%)      192 (5.9%)              178 (5.5%)              195 (6.1%)                      {txt}{c |}
  {c |} {res}   Missing                            9,043 (93.4%)   3,019 (93.3%)           3,027 (93.8%)           2,997 (93.2%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}Leflunomide within 12 months                                                                                                   0.88   {txt}{c |}
  {c |} {res}   Yes                                168 (1.7%)      58 (1.8%)               55 (1.7%)               55 (1.7%)                       {txt}{c |}
  {c |} {res}   No                                 467 (4.8%)      160 (4.9%)              145 (4.5%)              162 (5.0%)                      {txt}{c |}
  {c |} {res}   Missing                            9,043 (93.4%)   3,019 (93.3%)           3,027 (93.8%)           2,997 (93.2%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 6 months                                                                                                 0.22   {txt}{c |}
  {c |} {res}   Yes                                1,259 (13.0%)   405 (12.5%)             412 (12.8%)             442 (13.8%)                     {txt}{c |}
  {c |} {res}   No                                 4,525 (46.8%)   1,510 (46.6%)           1,544 (47.8%)           1,471 (45.8%)                   {txt}{c |}
  {c |} {res}   Missing                            3,894 (40.2%)   1,322 (40.8%)           1,271 (39.4%)           1,301 (40.5%)                   {txt}{c |}
  {c LT}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c RT}
  {c |} {res}bDMARD/tsDMARD within 12 months                                                                                                0.13   {txt}{c |}
  {c |} {res}   Yes                                2,633 (27.2%)   860 (26.6%)             867 (26.9%)             906 (28.2%)                     {txt}{c |}
  {c |} {res}   No                                 3,151 (32.6%)   1,055 (32.6%)           1,089 (33.7%)           1,007 (31.3%)                   {txt}{c |}
  {c |} {res}   Missing                            3,894 (40.2%)   1,322 (40.8%)           1,271 (39.4%)           1,301 (40.5%)                   {txt}{c |}
  {c BLC}{hline 37}{c -}{hline 15}{c -}{hline 23}{c -}{hline 23}{c -}{hline 23}{c -}{hline 9}{c BRC}
Data are presented as n (%).
 

{com}. restore
{txt}
{com}. 
{txt}end of do-file

{com}. exit, clear
